KLRA.US Kailera Therapeutics, Inc. Common Stock
- Market cap
- USD 1.72B
- P/E
- -
- P/B
- 1.67x
- ROE
- -37.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KLRA.US undervalued?
Graham numberThe Graham number of Kailera Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kailera Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Kailera Therapeutics, Inc. Common Stock yet.
Kailera Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glu…
Full company profileKailera Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kailera Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2025 | 2026 Anlz |
|---|---|---|
| Income Statement | ||
| Revenue | 0.00 | 0.00 |
| Operating Income | -158M | -416M |
| EBITDA | -158M | -403M |
| Net Income | -149M | -381M |
| EPS | -1.26 | -2.94 |
| Balance Sheet | ||
| Total Assets | 692M | 1.08B |
| Total Liabilities | 1.05B | 51.1M |
| Shareholders' Equity | -356M | 1.03B |
| Cash & Short-term Investments | 546M | 901M |
| Total Debt | 10.8M | 9.97M |
| Cash Flow | ||
| Operating Cash Flow | -120M | -373M |
| Capital Expenditure | 2.09M | 0.00 |
| Free Cash Flow | -122M | -373M |
| Ratios | ||
| ROE | - | -37.0% |
| ROA | -21.5% | -35.2% |
| Debt to Equity | - | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kailera Therapeutics, Inc. Common Stock dividends
Kailera Therapeutics, Inc. Common Stock has not paid dividends in the last 1 fiscal years.
Who owns Kailera Therapeutics, Inc. Common Stock
- Insiders 9.25%
- Institutions 90.75%
- Public & others 0.00%
- Shares outstanding 130M
- Free float 58.7M
Top funds holding KLRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 1.31M | 1.01% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.18M | 0.91% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.17M | 0.90% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 836K | 0.64% | -2.08% | Sep 2026 |
| Columbia Small Cap Growth Inst | 784K | 0.60% | 0.00% | Sep 2026 |
| Fidelity Growth Company Fund | 701K | 0.54% | 0.00% | Aug 2026 |
| Fidelity Select Biotechnology | 632K | 0.49% | +0.85% | Aug 2026 |
| T. Rowe Price Health Sciences | 627K | 0.48% | -42.78% | Sep 2026 |
| Eventide Healthcare & Life Sciences I | 617K | 0.47% | 0.00% | Jun 2026 |
| Fidelity Blue Chip Growth | 587K | 0.45% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 504K | 0.39% | 0.00% | Aug 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 465K | 0.36% | -4.54% | Sep 2026 |
| Columbia Acorn Inst | 463K | 0.36% | 0.00% | Sep 2026 |
| Federated Hermes Kaufmann Small Cap A | 404K | 0.31% | -7.02% | Sep 2026 |
| BlackRock Health Sciences Opps Inv A | 334K | 0.26% | 0.00% | Sep 2026 |
| T. Rowe Price New Horizons | 298K | 0.23% | -11.03% | Sep 2026 |
| CT (Lux) American Smaller Com 9U USD | 296K | 0.23% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 295K | 0.23% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 268K | 0.21% | +1.02% | Sep 2026 |
| Franklin Biotechnology Discv A(acc)USD | 254K | 0.20% | 0.00% | Sep 2026 |
Top institutions holding KLRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bain Capital Investors LLC | 26.3M | 20.22% | 0.00% | Jun 2026 |
| Bain Capital Life Sciences Investors, LLC | 22.6M | 17.39% | 0.00% | Jun 2026 |
| RTW INVESTMENTS, LLC | 10.8M | 8.30% | 0.00% | Jun 2026 |
| Canada Pension Plan Investment Board | 7.30M | 5.63% | 0.00% | Jun 2026 |
| Atlas Venture Life Science Advisors, LLC | 5.17M | 3.98% | 0.00% | Jun 2026 |
| FMR Inc | 3.97M | 3.06% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.93M | 3.03% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 3.53M | 2.72% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 3.24M | 2.50% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 3.21M | 2.47% | 0.00% | Jun 2026 |
| Wellington Management Company LLP | 2.92M | 2.25% | 0.00% | Jun 2026 |
| Royalty Pharma Sub-Manager, LLC | 2.46M | 1.89% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 2.21M | 1.71% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.69M | 1.30% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.65M | 1.27% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.13M | 0.87% | 0.00% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 1.10M | 0.85% | 0.00% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 1.10M | 0.85% | 0.00% | Jun 2026 |
| Trails Edge Capital Partners, LP | 985K | 0.76% | 0.00% | Jun 2026 |
| UBS Group AG | 973K | 0.75% | 0.00% | Jun 2026 |
Kailera Therapeutics, Inc. Common Stock company profile
- Company name
- Kailera Therapeutics, Inc. Common Stock
- Ticker
- KLRA.US
- Exchange
- USA Stocks
- Listed since
- Apr 17, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 145
- Fiscal year end
- December
- Address
- 180 Third Avenue, Waltham, MA, United States, 02451
- Phone
- 781 317 0290
- Website
- kailera.com
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Kailera Therapeutics, Inc. Common Stock management
10- Mr. Ronald C. Renaud Jr., M.B.A.President, CEO & Director · born 1969
- Mr. Paul Douglas Burgess J.D., M.S.Chief Operating & Business Officer · born 1974
- Ms. Jamie Beth ColemanChief Commercial Officer · born 1978
- Mr. Douglas W. Pagan M.B.A.Chief Financial Officer · born 1972
- Maura GavaghanVice President of Corporate Communications & Investor Relations
- Mr. Scott M. Akamine J.D.Chief Legal Officer & Secretary · born 1985
- Ms. Paula A. Cloghessy SHRM-SCP, SPHRChief People Officer · born 1972
- Dr. Scott M. Wasserman M.D.Chief Medical Officer · born 1970
- Ms. Kathleen Tregoning M.A.Chief Corporate Affairs Officer · born 1971
- Mr. Corey ManchesterTreasurer